

Paul H. Ratner, MD, Frank Hampel, MD, Julius Van Bavel, MD, N. J. Amar, MD; Pramila Daftary, MD, William Wheeler, PhD, and Harry Sacks, MD

Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis

Key words: allergic rhinitis, azelastine hydrochloride, fluticasone propionate nasal spray.

The most commonly used agents in the treatment of seasonal allergic rhinitis (SAR) are oral antihistamines and intranasal corticosteroids. Clinical studies [1, 2] have shown that the second-generation antihistamines, cetirizine and fexofenadine, provide approximately equal therapeutic efficacy, whereas the efficacy of cetirizine seems to exceed that of Loratadine [3–5]. Reviews [6, 7] of well-controlled clinical trials that directly compared an intranasal corticosteroid with an oral antihistamine.

Azelastine hydrochloride nasal spray is the only second-generation antihistamine recommended for the treatment of SAR and nonallergic vasomotor rhinitis [8, 9]. Compared with oral antihistamines, azelastine nasal spray significantly improved rhinitis symptom scores in placebo-controlled studies in patients with SAR who remained symptomatic after treatment with loratadine or fexofenadine. In these studies [10, 11] patients treated with azelastine nasal spray who received loratadine or fexofenadine concomitantly had no additional improvement when compared with treatment with azelastine nasal spray alone. In 2 direct comparative trials vs cetirizine in patients with SAR, azelastine nasal spray was significantly better than cetirizine for treating nasal symptoms in one trial [11, 12], numerically better than cetirizine in the second trial [13], and significantly better than cetirizine in both trials for improving quality of life variables using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

In 2-week, double-blind studies with intranasal corticosteroids in patients with SAR, azelastine nasal spray at a dosage of 1 spray per nostril twice daily showed comparable efficacy to budesonide, 2 sprays per nostril twice daily (400 µg/d) [14, 15] and tedomethasone (0,2 mg twice daily). In a 6-week double-blind trial in patients with SAR, azelastine, 1 spray per nostril twice daily, and loratadine, 10-mg tablets once daily, significantly ($P < 0,05$) improved symptom scores compared with baseline, and the physician global evaluation of

efficacy rated similar numbers of patients in each group with either «good» or «very good» improvement [17]. In a 2-week, double-blind trial in patients with SAR, azelastine, 1 spray per nostril twice daily, and cetirizine, 10 mg/d, produced total symptom score improvements of 61 % and 67 %, respectively [18]. In a 6-week, placebo-controlled study [19] in patients with perennial allergic rhinitis, a once-daily dose of 256 µg of budesonide aqueous suspension was significantly ($P < 0,01$) more effective than azelastine nasal spray, 1 spray per nostril twice daily, in improving the total nasal symptom score (TNSS). In a double-blind, placebo-controlled study [20] of flunisolide nasal spray and azelastine nasal spray in patients with perennial allergic rhinitis, the researchers reported little difference between the 2 treatments for the overall summary score; however, the topical corticosteroid showed a greater decrease in symptom severity compared with placebo than the antihistamine spray for all symptoms, except rhinorrhea.

Unfortunately, many patients with SAR do not achieve optimal symptom relief with single-agent therapy. In a survey conducted by the American College of Allergy, Asthma & Immunology, more than 75 % of allergists and primary care physicians surveyed cited inadequate symptom relief as the reason for changing medications or prescribing combination therapy [11]. Although oral antihistamines and intranasal corticosteroids routinely are prescribed together, the weight of clinical evidence indicates that combination therapy with these agents is no more effective than the corticosteroid alone [7, 22, 23]. To our knowledge, there have been no published studies that evaluated the efficacy of azelastine nasal spray used in combination with an intranasal corticosteroid. We hypothesized that 2 agents with different mechanisms of action could have the potential for a greater effect when used in combination than separately. The antihistamine effect of azelastine would be evident quickly after initial administration and sustained with regular use. The primary antihista-

mine activity of azelastine could be augmented by antiinflammatory effects of the intranasal corticosteroid during the 2-week study period. Therefore, this study was conducted to determine if greater efficacy could be achieved with the combination of intranasal azelastine and intranasal fluticasone propionate when compared with the efficacy of either agent alone in patients with SAR.

Methods

Patients

The study population consisted of patients 12 years and older with a minimum 2-year history of allergy to Texas mountain cedar (*Juniperus ashei*) pollen, as confirmed by a positive allergy skin test result within the past year. Use of concomitant medications was discontinued for specified times, based on the elimination half-life of each drug, before patients began the double-blind treatment period. All patients or their guardians (if the patient was aged < 18 years) signed an institutional review board-approved informed consent agreement (Sterling institutional review board, Atlanta, Georgia) before participation.

Study design

This randomized, double-blind, double-dummy, parallel-group study was conducted between December 27, 2005, and February 17, 2006, at 5 investigational sites during the Texas mountain cedar season. Pollen counts were conducted at each study site to confirm the presence of mountain cedar pollen during the investigation. The objective was to determine if greater efficacy could be achieved with the combination of azelastine hydrochloride nasal spray (Astelin; MedPointe Pharmaceuticals, Somerset, New Jersey) and fluticasone propionate nasal spray (Flonase; GlaxoSmithKline, Research Triangle Park, North Carolina) compared with the efficacy of each agent alone.

The primary efficacy variable was the change from baseline to day 14 for the entire double-blind treatment period in the TNSS, consisting of rhinorrhea, sneezing, itchy nose, and nasal congestion. Secondary efficacy variables included the following: (1) change from baseline for each individual treatment day, (2) change from baseline to day 14 in individual symptom scores, and (3) change from baseline to day 14 in the RQLQ, including overall score and individual domains. Safety was evaluated by patient reports of adverse experiences and vital sign assessments, including body temperature, blood pressure, pulse rate, and respiration rate, performed at baseline and at the end of the study.

There were 10 symptom assessments (in the morning and evening each day) during the 5-day placebo lead-in period. To qualify for randomization to the double-blind treatment period, patients must have recorded a 12-hour reflective TNSS of at least 8 at 3 evaluation times either in the morning or in the evening (1 of which was within 48 hours of study day 1) during the lead-in period. In addition, a morning or evening nasal congestion score of 3 must have been recorded at 3 assessments (1 of which was within 48 hours of day 1).

Patients randomized to the azelastine nasal spray group received azelastine nasal spray, 2 sprays per nostril twice daily, in the morning and evening (1,1-mg azelastine) and placebo

spray once daily in the morning. Patients randomized to the fluticasone group received fluticasone, 2 sprays per nostril once daily, in the morning (200- μ g fluticasone) and placebo spray twice daily in the morning and evening. Patients randomized to the combination group received azelastine nasal spray, 2 sprays per nostril twice daily, in the morning and evening and fluticasone nasal spray, 2 sprays per nostril once daily, in the morning. The kits containing study drugs were assembled so that blinded azelastine nasal spray was administered before blinded fluticasone nasal spray.

Patients were instructed to administer the morning doses of each study drug 15 to 30 minutes apart. Instruction on proper technique for administering the nasal sprays was given before starting the lead-in period and again before the double-blind treatment period, and patients were observed taking their initial dose, of study medications before leaving the clinic at these visits.

The identity of the study medications was concealed through use of a device (Pharmask inc., Medfield, Massachusetts) that prevented identification of the product but allowed for the proper administration of the nasal sprays.

During the 2-week, double-blind treatment period, the patients recorded symptom scores twice daily (morning and evening) on diary cards. Symptoms were recorded before the morning and evening doses of study medications as an evaluation of symptom severity during the previous 12 hours (12-hour reflective TNSS). Individual symptoms of the TNSS were scored on a 4-point scale, where 0 indicates no symptoms; 1, mild symptoms; 2, moderate symptoms; and 3, severe symptoms (such that the maximum combined morning and evening TNSS was 24).

Statistical analysis

Patients were randomized to treatment by a computer-generated randomization schedule, which was accessible only to authorized persons who were not involved in the study. The primary efficacy analyses were performed on an intent-to-treat population consisting of all randomized patients with at least 1 postbaseline observation. Missing TNSS values were imputed using the last-observation-carried-forward method. Safety analyses were performed on all randomized patients who received at least 1 dose of study medication.

The effects of treatment were determined at each day of the study and after 14 days based on change from baseline in the TNSS. Baseline TNSS was defined as the average of all TNSS scores during the 5-day placebo lead-in period. The treatment groups were compared using an analysis of variance model with baseline as a covariate. The data from this study were tested for homogeneity and were normally distributed. No site-related effects were identified. The TNSS was analyzed as the mean change from baseline during the entire 14-day study period. Additional analyses included the mean change from baseline in TNSS for individual study days and individual symptoms and the mean percentage change from baseline during the entire 14-day study period.

The quality-of-life evaluation was performed using the self-administered RQLQ, which evaluated the following 7 domain: (1) activities, (2) sleep, (3) non-nose/eye symptoms, (4) practical problems, (5) nasal symptoms, (6) eye-symptoms, and

Demographic and baseline characteristics					Table 1
Characteristic	Azelastine hydrochloride nasal spray group (n = 49)	Fluticasone propionate nasal spray group (n = 50)	Combination azelastine nasal spray and fluticasone nasal spray group (n = 52)	Total (n = 151)	
Age, y					
Mean	38,4	37,4	36,0	37,2	
Range	12–73	12–72	13–70	12–73	
Sex, No. (%)					
Males	22 (44,9)	15 (30,0)	19 (36,5)	56 (37,1)	
Females	27 (55,1)	35 (70,0)	33 (63,5)	95 (62,9)	
Race/ethnicity, No. (%)					
White	36 (73,5)	32 (64,0)	41 (78,8)	109 (72,2)	
Black	5 (10,2)	2 (4,0)	2 (3,8)	9 (6,0)	
Asian	0	3 (6,0)	1 (1,9)	4 (2,6)	
Hispanic	7 (14,3)	13 (26,0)	8 (15,4)	28 (1,5)	
Other	1 (2,0)	0	0	1 (0,7)	
Baseline TNSS					
Mean	19,6	19,5	19,5	19,5	
SD	2,11	2,74	2,97	2,62	
Range	15–24	14–24	13–24	13–24	
Duration of allergy, y					
Mean	19–2	15–7	16,2	17,0	
Range	3–50	3–51	4–40	3–51	
Abbreviation: TNSS, total nasal symptom score, a percentages may not total 100 because of rounding.					

(7) emotional factors. The change from baseline to day 14 in the RQLQ domains and overall score was calculated and analyzed according to the method described by Juniper et al. [24].

The incidence of adverse events was summarized by body system, severity, and relationship to study drug. Vital sign measurements, including oral body temperature, systolic and diastolic blood pressure, pulse rate, and respiration rate, were examined for abnormal values and changes from baseline.

Results

Disposition of Patients

A total of 151 patients were randomized to double-blind treatment at 5 study centers. Of the 151 randomized patients, 150 had postbaseline diary data and were included in the efficacy analysis. Data for all 151 randomized patients were included in the safety analysis. A total of 147 patients Completed all 14 days of the double-blind treatment period. All of the patients in the azelastine nasal spray group completed 14 study days. In the fluticasone group, 1 patient withdrew consent and 1 withdrew for lack of efficacy. In the

combination group, 2 patients were withdrawn for noncompliance with the protocol.


Demographic Characteristics

The treatment groups were comparable for baseline demographic and clinical characteristics (Table 1). The patients were a mean age of 37,2 years (range, 12–73 years), most were female, and the average duration of allergy to Texas mountain cedar was 17 years.

Primary Efficacy

Primary efficacy was change from baseline to day 14 in TNSS. Table 2 provides the mean improvements in the TNSS and individual symptoms for the 3 treatment groups. The treatment groups were comparable for baseline symptom scores, and all 3 treatments resulted in statistically significant ($P < 0,001$) improvements from baseline. The mean \pm SD improvement from the baseline TNSS was $4,8 \pm 4,3$ with azelastine nasal spray, $5,2 \pm 4,6$ with fluticasone nasal spray, and $7,4 \pm 5,6$ with the 2 agents in combination. The TNSS improved from baseline by 27,1 % with intranasal fluticasone, by 24,8 % with azelastine nasal spray, and by 37,9 % with the

Data for the TNSS								
Variable	Baseline data		Change from baseline TNSS data			Change from baseline TNSS data, %		
	LS Mean	SD	LS Mean	SD	P value	LS Mean, %	SD	P value
TNSS								
Azelastine hydrochloride nasal spray plus fluticasone propionate nasal spray	19,5	3,0	7,4	5,6		37,9	27,7	N/A
Azelastine hydrochloride nasal spray alone	19,7	2,1	4,8	4,3	0,008	24,8	22,2	0,01
Fluticasone propionate nasal spray alone	19,6	2,7	5,2	4,6	0,03	27,1	24,5	0,04
Itchy nose								
Azelastine hydrochloride nasal spray plus fluticasone propionate nasal spray	4,7	1,0	1,9	1,7	N/A	39,9	39,0	N/A
Azelastine hydrochloride nasal spray alone	4,8	0,8	1,1	1,4	0,009	25,4	29,7	0,3
Fluticasone propionate nasal spray alone	4,8	1,3	1,3	1,5	0,02	25,5	32,9	0,4
Congestion								
Azelastine hydrochloride nasal spray plus fluticasone propionate nasal spray	5,4	0,6	1,7	1,4	N/A	31,2	25,7	N/A
Azelastine hydrochloride nasal spray alone	5,5	0,5	1,1	1,5	0,02	19,2	26,6	0,02
Fluticasone propionate nasal spray alone	5,5	0,4	1,1	1,2	0,04	21,1	23,4	0,04
Runny nose								
Azelastine hydrochloride nasal spray plus fluticasone propionate nasal spray	4,9	1,0	1,7	1,6	N/A	36,4	32,9	N/A
Azelastine hydrochloride nasal spray alone	4,9	0,8	1,1	1,4	0,02	20,5	27,6	0,05
Fluticasone propionate nasal spray alone	5,0	1,0	1,3	1,2	0,19	23,0	53,4	0,09
Sneezing								
Azelastine hydrochloride nasal spray plus fluticasone propionate nasal spray	4,5	1,2	2,1	1,7	N/A	46,4	37,2	N/A
Azelastine hydrochloride nasal spray alone	4,5	1,1	1,5	1,0	0,04	34,2	25,8	0,08
Fluticasone propionate nasal spray alone	4,3	1,3	1,5	1,5	0,05	31,8	38,1	0,04
Abbreviations: LS – least squares; NA – data not applicable; TNSS – total nasal symptom score. a Data were available for 52 patients in the combination therapy group, 49 in the azelastine nasal spray group, and 49 in the fluticasone nasal spray group. b Statistical significance of azelastine nasal spray plus fluticasone nasal spray vs the individual agent. c One patient had no postbaseline efficacy assessment and was not included in the analysis.								



* – Azelastine + Fluticasone; $P < 0,05$ vs Fluticasone
– Azelastine + Fluticasone; $P < 0,05$ vs Azelastine

Figure 1. Total nasal symptom scores (TNSS) and individual symptoms.

* – indicates $P < 0,05$ for azelastine hydrochloride plus fluticasone propionate vs fluticasone alone;
– $P < 0,05$ for azelastine plus fluticasone vs azelastine alone


2 agents in combination ($P < 0,05$ vs either agent alone); there were absolute improvements of 11 % and 13 % with combination therapy compared with intranasal azelastine and fluticasone, respectively. These absolute improvements represent greater than 40 % relative improvement compared with either agent alone ($P = 0,007$ vs azelastine and $P = 0,02$ vs fluticasone).

Secondary Efficacy

Change from baseline to day 14 in individual symptoms. Combination therapy improved all individual TNSS symptoms compared with the individual agents (Fig 1). Combination therapy provided 48 % more relief from nasal congestion and 56 % more relief from nasal itching than fluticasone alone, and the combination was statistically superior to both azelastine and fluticasone. Combination therapy provided 58 % more relief from runny nose than fluticasone alone, and the combination was statically superior to azelastine. Combination therapy provided 46 % more relief from sneezing than fluticasone alone, and the combination was statistically superior to fluticasone.

Change from baseline to day 14 in TNSS on individual study days. Figure 2 shows the improvement in the 3 treatment groups on each individual day of the study. The combination of azelastine and fluticasone was statistically superior to azelastine alone on study days 3 through 14, and the combination was statistically superior to fluticasone alone on days 4 and 6 through 11.

Change from baseline to day 14 in RQLQ scores. All 3 treatments produced statistically significant ($P < 0,001$) improvements from their respective baseline RQLQ scores for overall score and for each individual domain of the RQLQ (Table 3). The mean change from baseline in the overall RQLQ score was 1,21 in the azelastine nasal spray group, 1,47 in the fluticasone group, and 1,92 in the combination group, which was statistically significant compared with azelastine and approached significance compared with fluticasone.



* – $P < 0,05$ vs Azelastine
– $P < 0,05$ vs Fluticasone

Figure 2. Total nasal symptom SCORE (TNSS) daily improvements.

* – indicates $P < 0,05$ for azelastine hydrochloride plus fluticasone propionate vs azelastine alone;
– $P < 0,05$ for azelastine plus fluticasone vs fluticasone alone.

Safety

All 3 treatments were well tolerated. The most common adverse event was the bitter taste associated with azelastine (8,2 % in the azelastine group, 2,0 % in the fluticasone group, and 13,5 % in the combination group). Headache was reported by 4,1 % of patients in the azelastine group, by 4,0 % of patients in the fluticasone group, and by 5,8 % of patients in

the combination group. No other adverse event was reported by more than 1 patient. There were no significant changes from baseline to the end of the study in vital sign assessments.

Discussion

In this study significantly greater efficacy was achieved by combination therapy with an antihistamine nasal spray and an intranasal (corticosteroid spray, when compared with either agent alone. Azelastine nasal spray plus fluticasone nasal spray provided greater than 40 % relief of the TNSS relative to fluticasone alone and greater than 48 % relief of nasal congestion relative fluticasone alone. All of the individual symptoms of the TNSS were improved with combination therapy when compared with either fluticasone or azelastine alone. This improvement reached statistical significance compared with azelastine on day 3 and compared with both fluticasone and azelastine on day 4, and the improvement in TNSS steadily increased with combination therapy during the 14-day study period.

The combination regimen was well tolerated by the patients in this study. Compliance was evaluated by patient diary entries and confirmed by bottle weights measured before and after the double-blind treatment period. Compliance was greater than 98 % in each treatment group. Other than a small increase in the incidence of bitter taste and headache in the combination group, no other adverse event was reported by more than 1 patient. In particular, there was no increase in the incidence of nasal irritation or epistaxis with azelastine nasal spray and fluticasone nasal spray in combination. As expected, there were no significant changes from baseline to the end of the study in vital sign assessments.

Overall RQLQ and Individual Domain Scores					Table 3
			P value		
RQLQ score by treatment group	Baseline LS value, mean (SD)	LS change from baseline, mean (SD)	Compared with azelastine hydrochloride alone	Compared with fluticasone propionate alone	
Overall score					
Azelastine group	3,66 (1,13)	1,21 (1,02)	N/A	N/A	
Fluticasone group	3,95 (1,14)	1,47 (1,21)	N/A	N/A	
Azelastine plus fluticasone group	3,93 (1,09)	1,92 (1,46)	0,005	0,08	
Activities					
Azelastine group	4,17 (1,18)	1,37 (1,38)	N/A	N/A	
Fluticasone group	4,45 (0,97)	1,52 (1,64)	N/A	N/A	
Azelastine plus fluticasone group	4,55 (1,10)	2,03 (1,70)	0,04	0,12	
Sleep					
Azelastine group	3,25 (1,24)	1,23 (1,08)	N/A	N/A	
Fluticasone group	3,91 (1,40)	1,23 (1,56)	N/A	N/A	
Azelastine plus fluticasone group	3,81 (1,27)	1,88 (1,66)	0,02	0,02	
Non-nose/eye symptoms					
Azelastine group	3,22 (1,28)	0,88 (1,23)	N/A	N/A	
Fluticasone group	3,48 (1,30)	1,19 (1,36)	N/A	N/A	
Azelastine plus fluticasone group	3,40 (1,38)	1,52 (1,46)	0,01	0,20	
Practical problems					
Azelastine group	4,28 (1,30)	1,59 (1,58)	N/A	N/A	
Fluticasone group	4,55 (1,33)	1,74 (1,51)	N/A	N/A	
Azelastine plus fluticasone group	4,48 (1,23)	2,29 (1,62)	0,02	0,07	
Nasal symptoms					
Azelastine group	4,31 (1,25)	1,46 (1,31)	N/A	N/A	
Fluticasone group	4,65 (1,19)	1,72 (1,38)	N/A	N/A	
Azelastine plus fluticasone group	1,62 (1,24)	2,19 (1,51)	0,006	0,06	
Eye symptoms					
Azelastine group	3,76 (1,53)	1,64 (1,58)	N/A	N/A	
Fluticasone group	4,02 (1,56)	1,51 (1,37)	N/A	N/A	
Azelastine plus fluticasone group	4,04 (1,58)	2,18 (1,86)	0,07	0,02	
Emotions					
Azelastine group	3,20 (1,60)	1,26 (1,19)	N/A	N/A	
Fluticasone group	3,55 (1,51)	1,42 (1,53)	N/A	N/A	
Azelastine plus fluticasone group	3,43 (1,47)	1,68 (1,72)	0,15	0,40	
Abbreviations: LS – least squares; N/A – data not applicable; RQLQ – Rhinoconjunctivitis Quality of Life Questionnaire. Data are given for patients 18 years and older. An analysis of variance model was used.					

Virtually all of the patients seen in allergy specialty practice have tried at least 1 allergy medication without success, and many patients require more than 1 medication to achieve a satisfactory degree of symptom control. Although combination therapy frequently is prescribed, there are relatively few published clinical studies that have evaluated combination therapies for allergic rhinitis. Nielsen and Dahl [7] analyzed pertinent medical literature published between 1966 and 2001 and reported no striking differences in efficacy among the intranasal corticosteroids for treating allergic rhinitis and no clinical evidence to support the practice of combining an intranasal corticosteroid with an oral antihistamine. Review articles by Akertund et al [22] and Howarth [23] also reported no evidence to suggest that a clinical benefit can be achieved by combining an intranasal corticosteroid and an oral antihistamine in the treatment of allergic rhinitis.

The substantial improvements with combination therapy in the present study suggest that in addition to differences in mechanism of action between antihistamines and corticosteroids, the ability to direct the medication to the target tissue is an important determinant of the effectiveness of this combination. In contrast to oral antihistamines, intranasal delivery targets the nasal mucosa, the site of allergic inflammation; reduces the risk of systemic adverse effects and drug interactions; and possibly enhances anti allergic and antiinflammatory effects by [25] increasing local tissue concentrations [26].

There are no known contraindications regarding concomitant use of azelastine nasal spray and an intranasal corticosteroid. If azelastine nasal spray and intranasal fluticasone are used together, the dosage and administration of each agent can be tailored to individual needs with regard to the total number of sprays per day and the timing of the doses. Patients with moderate to severe symptoms can receive the highest recommended dosages when therapy begins and then the dosage can be adjusted downward if symptoms improve, whereas patients with less severe symptoms can receive lower dosages when therapy begins, with dosage increases if adequate symptom relief is not achieved.

The economic burden of allergic rhinitis is substantial and includes the direct medical costs of physician visits and medications and the indirect costs related to reductions in productivity because of rhinitis symptoms or the effects of treatment. Although methods vary, the annual direct cost of rhinitis has been estimated to be as much as \$ 5 billion (updated to 2003 US dollars) and annual indirect costs as much as \$ 9,7 billion [27]. With allergic, nonallergic, and mixed rhinitis affecting up to 60 million persons in the United States annually [9, 28], the costs of treatment must be viewed in light of the potential clinical benefit. Ineffective treatment leads to patient frustration, dissatisfaction, and poor compliance. Physicians may likewise become frustrated that patients do not adhere to their prescribed treatment regimens despite their efforts to educate them.

Considering the efficacy of combination therapy that was demonstrated in this trial, the lower cost associated with generic fluticasone and the widespread preferred formulary status of azelastine nasal spray, which entails lower out-of-pocket cost to the patient compared with second-generation oral antihistamines, the combination of azelastine nasal spray

and fluticasone nasal spray may be cost-effective for patients with moderate to severe or persistent seasonal allergies.

The high baseline symptom scores reported by the patients are indicative of the severity of rhinitis symptoms that can be caused by Texas mountain cedar pollen. In this patient population, azelastine nasal spray in combination with fluticasone nasal spray provided 40 % or more relief of nasal SAR symptoms relative to fluticasone nasal spray alone. Combination therapy began to improve symptoms within 24 hours compared with the individual agents, and increasing improvement was observed throughout the 14-day study period. The combination was well tolerated; only bitter taste and headache were reported as adverse events by more than 1 patient.

The use of intranasal azelastine in combination with intranasal fluticasone produced an unanticipated magnitude of improvement in rhinitis symptoms among patients with allergy to Texas mountain cedar pollen. The 40 % or greater improvement in the TNSS relative to the individual agents is in contrast to previously published studies that showed no appreciable benefit with an oral antihistamine and an intranasal corticosteroid in combination. Azelastine nasal spray and fluticasone nasal spray used in combination may provide a substantial clinical benefit for patients with SAR compared with therapy with either agent alone.

References

1. Howarth, P. H. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis [Text] / P. H. Howarth [et al.] // J. Allergy Clin. Immunol. — 1999. — Vol. 104. — P. 927–933.
2. Hampel, F. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis [Text] / F. Hampel [et al.] // Ann Allergy Asthma Immunol. — 2003. — Vol. 91. — P. 354–361.
3. Day, J. H. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit [Text] / J. H. Day, M. Briscoe, M. D. Widlitz // J. Allergy Clin. Immunol. — 1998. — Vol. 101. — P. 638–645.
4. Day, J. H. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system [Text] / J. H. Day [et al.] // Ann Allergy Asthma Immunol. — 2001. — Vol. 87. — P. 474–481.
5. Meitzer, E. O. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis [Text] / E. O. Meitzer, J. M. Weiler, M. D. Widlitz // J. Allergy Clin. Immunol. — 1996. — Vol. 97. — P. 617–626.
6. Weiner, J. M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials [Text] / J. M. Weiner, M. J. Abramson, R. M. Puy // BMJ. — 1998. — Vol. 317. — P. 1624–1629.
7. Nielsen, L. P. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis [Text] / L. P. Nielsen, R. Dahl // Ann J. Respir. Med. — 2003. — Vol. 2. — P. 55–65.
8. Bousquet, H. Allergic rhinitis and its impact on asthma [Text] / H. Bousquet, P. van Cauwenberge, N. J. Kjaltaev // Allergy Clin. Immunol. — 2001. — Vol. 108 (suppl. 5). — S. 147–S. 334.
9. Dykewicz, M. S. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on practice parameters in allergy, asthma and immunology [Text] / M. S. Dykewicz [et al.] // Ann Allergy Asthma Immunol. — 1998. — Vol. 81. — P. 478–518.
10. Berger, W. E. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine [Text] / W. E. Berger [et al.] // Ann Allergy Asthma Immunol. — 2003. — Vol. 91. — P. 205–211.

11. *LaForce, C. F.* Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients remaining symptomatic after treatment with fexofenadine [Text] / C. F. LaForce, J. Corren, W. J. Wheeler, W.E. Berger // *Ann Allergy Asthma Immunol.* — 2004. — Vol. 93. — P. 154–159.
12. *Corren, S.* Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis [Text] / S. Corren [et al.] // *Clin. Ther.* — 2005. — Vol. 27. — P. 543–553.
13. *Berger, W. E.* Impact of azelastine nasal spray on symptoms and quality of life compared to cetirizine oral tablets in patients with seasonal allergic rhinitis [Text] / W. E. Berger [et al.] // *Ann Allergy Asthma Immunol.* — 2006. — Vol. 97. — P. 375–381.
14. *Dorow, P.* Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide [Text] / P. Dorow, R. Atirich, U. Peteold // *Arzneimittelforschung.* — 1993. — Vol. 43. — P. 909–912.
15. *Wang, D.* Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season [Text] / D. Wang, J. Smits, M. DeWaele, P. Clement // *Int. Arch. Allergy Immunol.* — 1997. — Vol. 114. — P. 185–192.
16. *Newson-Smith, G.* A placebo-controlled study comparing the efficacy of intranasal azelastine and betamethasone in the treatment of seasonal allergic rhinitis [Text] / G. Newson-Smith [et al.] // *Eur. Arch. Otorhinolaringol.* — 1997. — Vol. 254. — P. 236–241.
17. *Gambardella, R.* A comparison of the efficacy of azelastine nasal spray and loratadine tablets in the treatment of seasonal allergic rhinitis [Text] / R. Gambardella // *J. Int. Med. Res.* — 1993. — Vol. 21. — P. 268–275.
18. *Charpin, D.* A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine [Text] / D. Charpin // *Eur. Arch. Otorhinolaringol.* — 1995. — Vol. 252. — P. 455–458.
19. *Stern, M. A.* Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine [Text] / M. A. Stern [et al.] // *Ann Allergy Asthma Immunol.* — 1998. — Vol. 81. — P. 354–358.
20. *Berlin, J. M.* Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis [Text] / J. M. Berlin [et al.] // *J. Ann Osteopath Assoc.* — 2000. — Vol. 100 (suppl.). — S8–S13.
21. *Physician Survey* Sponsored by the American College of Allergy // *Asthma & Immunology.* Rochester. — NY: Haris Interactive Inc., 2001.
22. *Akerlund, A.* Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication [Text] / A. Akerlund [et al.] // *J. Allergy Clin. Immunol.* — 2005. — Vol. 115. — S460–S482.
23. *Howarth, P. H.* A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis [Text] / P. H. Howarth // *Allergy.* — 2000. — Vol. 62. — P. 6–11.
24. *Juniper, E. F.* Validation of the standardized version of the rhinoconjunctivitis quality of life questionnaire [Text] / E. F. Juniper, A. K. Thompson, P. J. Ferric, J. N. Roberts // *J. Allergy Clin. Immunol.* — 1999. — Vol. 104. — P. 364–369.
25. *Sulib, J. R.* Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis [Text] / J. R. Sulib, P. H. Howarth // *Drug Saf.* — 2003. — Vol. 26. — P. 863–893.
26. *Davies, R. J.* Antihistamines: topical vs oral administration [Text] / R. J. Davies [et al.] // *Clin. Exp. Allergy.* — 1996. — [et al.] // Vol. 26 (suppl. 3). — P.11–17.
27. *Reed, S. D.* The economic burden of allergic rhinitis: a critical evaluation of the literature [Text] / S. D. Reed, T. A. Lee, D.C. McCrory // *Pharmacoeconomics.* — 2004. — Vol. 22. — P. 345–361.
28. *Settipane, R. A.* Demographics and epidemiology of allergic and nonallergic rhinitis [Text] / R. A. Settipane // *Allergy Asthma Proc.* — 2001. — Vol. 22. — P. 185–189.

Ann Allergy Asthma Immunol. 2008;100:74–81